Key Points. Time-limited triple therapy leads to high rates of undetectable minimal residual disease and sustained remissions in high-risk CLL.Adverse events oc
The novel EHA/EBMT grading of ICAHT closely reflects the extent of hematological toxicity following BCMA- and CD19-directed CAR-T therapy.Severe ICAHT was
Key Points. Obinutuzumab can safely be used in combination with chemotherapy and in maintenance after ASCT as frontline therapy in MCL patients.Obinutuzuma
Abstract. The routine use of next-generation sequencing methods has underscored the genetic and clonal heterogeneity of acute myeloid leukemia (AML), subsequent
Abstract. Treatment options for acute myeloid leukemia (AML) have expanded over the last 5 years. New regimens are increasing the options for patients who
Abstract. Intensive chemotherapy in combination with allogeneic hematopoietic cell transplantation and supportive care can induce long-term remissions in a
Key Points. High-dose alemtuzumab led to effective suppression of chronic GVHD.Lymphodepletion delays Tn recovery resulting in lower TCR repertoire and hig
Gulrayz Ahmed, Aseel Alsouqi, Aniko Szabo, Laura Samples, Mazyar Shadman, Farrukh T Awan, Alexandra E. Rojek, Peter A Riedell, Madiha Iqbal, Timothy S. Fen
In this issue of Blood, Fuchs et al1 have used T-cell biology, coupled with Genome Wide Association Studies (GWAS) and computational leverage of public dat
In this issue of Blood, Fuchs et al1 have used T-cell biology, coupled with Genome Wide Association Studies (GWAS) and computational leverage of public dat
Sonrotoclax is a potent and selective BCL2 inhibitor that is also effective in venetoclax-resistant BCL2 mutants both in vitro and in vivo.The crystal stru
